Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) had its target price hoisted by research analysts at Cantor Fitzgerald from $56.00 to $62.00 in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 10.03% from the stock’s previous close.

AERI has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a report on Wednesday, May 3rd. Needham & Company LLC boosted their price objective on Aerie Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, May 25th. Cowen and Company reissued an “outperform” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Canaccord Genuity set a $56.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $65.67.

Aerie Pharmaceuticals (AERI) traded up 2.27% on Thursday, hitting $56.35. 760,917 shares of the stock were exchanged. The firm’s market cap is $1.90 billion. Aerie Pharmaceuticals has a 52-week low of $16.61 and a 52-week high of $59.50. The company has a 50-day moving average price of $53.84 and a 200-day moving average price of $46.44.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. On average, equities research analysts anticipate that Aerie Pharmaceuticals will post ($2.57) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/20/aerie-pharmaceuticals-inc-nasdaqaeri-price-target-raised-to-62-00-at-cantor-fitzgerald.html.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $55.95, for a total value of $1,119,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.36% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Legato Capital Management LLC bought a new stake in shares of Aerie Pharmaceuticals during the second quarter valued at $2,129,000. Aperio Group LLC increased its stake in shares of Aerie Pharmaceuticals by 4.7% in the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock valued at $258,000 after buying an additional 219 shares during the last quarter. Handelsinvest Investeringsforvaltning bought a new stake in shares of Aerie Pharmaceuticals during the second quarter valued at $2,381,000. Fox Run Management L.L.C. increased its stake in shares of Aerie Pharmaceuticals by 25.5% in the second quarter. Fox Run Management L.L.C. now owns 12,000 shares of the company’s stock valued at $631,000 after buying an additional 2,442 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its stake in shares of Aerie Pharmaceuticals by 78.1% in the second quarter. Handelsbanken Fonder AB now owns 130,000 shares of the company’s stock valued at $6,832,000 after buying an additional 57,000 shares during the last quarter. Hedge funds and other institutional investors own 91.90% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.